Since the introduction of the epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and their approval for clinical use in the treatment of advanced NSCLC, the critical question of how to optimize EGFR-TKI therapeutic efficacy in NSCLC patients was raised20. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.